Aldeyra Therapeutics (Aldeyra Therapeutics) EBIT : $-35.47 Mil (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Aldeyra Therapeutics EBIT?

Aldeyra Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-4.24 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-35.47 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Aldeyra Therapeutics's annualized ROC % for the quarter that ended in Dec. 2023 was -128.96%. Aldeyra Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -5,757.56%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Aldeyra Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -33.27%.

Aldeyra Therapeutics EBIT Historical Data

The historical data trend for Aldeyra Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aldeyra Therapeutics EBIT Chart

Aldeyra Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-61.53

-36.13

-56.03

-60.33

-35.47

Aldeyra Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															-12.44	-15.12	-8.46	-7.65	-4.24

Competitive Comparison of Aldeyra Therapeutics's EBIT

For the Biotechnology subindustry, Aldeyra Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aldeyra Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aldeyra Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Aldeyra Therapeutics's EV-to-EBIT falls into.

Aldeyra Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.47 Mil.

Aldeyra Therapeutics (NAS:ALDX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Aldeyra Therapeutics's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-24.392 * ( 1 - 0% )	/	( (18.839	+	18.99)	/ 2 )
=	-24.392	/	18.9145
=	-128.96 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	147.282	-	2.85	-	( 143.335	-	max(0, 21.617	-	147.21	+	143.335	))
=	18.839

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	148.327	-	3.787	-	( 142.823	-	max(0, 22.26	-	147.81	+	142.823	))
=	18.99

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Aldeyra Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-16.956	/	( ( (0.072 + max(-4.215, 0))	+	(0.517 + max(-1.887, 0)) )	/	2 )
=	-16.956	/	( ( 0.072	+	0.517 )	/	2 )
=	-16.956	/	0.2945
=	-5,757.56 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	3.875)	-	(2.85	+	0	+	5.24)
=	-4.215

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	4.987)	-	(3.787	+	0	+	3.087)
=	-1.887

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Aldeyra Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-35.471	/	106.630
	=	-33.27 %

Aldeyra Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of Aldeyra Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Aldeyra Therapeutics (Aldeyra Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aldeyra Therapeutics Inc (NAS:ALDX) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

137:Germany 137:Germany

Address

131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421

Website

https://www.aldeyra.com

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

Executives

Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Todd C Brady	director, officer: President and CEO	C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Martin Joseph Joyce	director	1050 HINGHAM STREET, ROCKLAND MA 02370
Bruce Greenberg	officer: See Remarks	C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Stephen Machatha	officer: Chief Development Officer	131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Richard Douglas	director	ONE KENDALL SQUARE, CAMBRIDGE MA 02139
Nancy Miller-rich	director	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001
Ben Bronstein	director	15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
David J Clark	officer: Chief Medical Officer	131 HARTWELL AVE, LEXINGTON MA 02421
David Mcmullin	officer: SVP Corp. Dev. & Strategy	C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Joshua Reed	officer: Chief Financial Officer	C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Jesse I Treu	director, 10 percent owner
Stephen J Tulipano	officer: Chief Financial Officer	C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140